MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program
The company will engage in BIO One-on-One Partnering™ meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study in neuropathic pain, and finalizes filings for SKNY acquisition.
MIAMI, FL / ACCESS Newswire / May 28, 2025 / MIRA Pharmaceuticals, Inc. (Nasdaq:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced that it will participate in the BIO International Convention 2025, taking place in Boston, MA from June 16-19, 2025. The Company has a full schedule of BIO One-on-One Partnering™ meetings planned as it explores potential licensing, strategic partnerships, and M&A opportunities.
The Company's lead candidate, Ketamir-2, a next-generation oral ketamine analog, is currently undergoing a Phase 1 clinical trial. With the second dosing cohort completed, the Company is now preparing to initiate the third cohort. Building on this momentum, MIRA anticipates initiating a Phase IIa study in neuropathic pain before the end of the year, advancing the development of what the Company believes could be a safe, effective non-opioid alternative for chronic pain management.
In addition, MIRA is advancing a series of preclinical studies with Ketamir-2, including models evaluating its potential in PTSD, as well as a topical formulation aimed at treating localized inflammatory pain. The Company is also finalizing regulatory filings related to its acquisition of SKNY Pharmaceuticals, Inc. ("SKNY"), with submission to the U.S. Securities and Exchange Commission (SEC) expected in the coming weeks. SKNY-1, SKNY's primary pharmaceutical candidate, is being developed as an oral therapeutic targeting smoking cessation and obesity, with activity at CB1, CB2, and MAO-B receptors.
"Our pipeline is advancing on all fronts, and we are focused on turning this scientific momentum into long-term value for patients and shareholders," said Erez Aminov, Chief Executive Officer of MIRA. "As we move closer to initiating Phase IIa and completing the SKNY transaction, we're actively exploring strategic opportunities to accelerate growth, including licensing and partnerships-especially in areas like chronic pain where non-opioid alternatives like Ketamir-2 are urgently needed."
Dr. Angel, Chief Scientific Advisor at MIRA, added:"We believe Ketamir-2 is paving the way for a new class of non-opioid therapies. The science is compelling, and the progress we have made is truly exciting. I look forward to sharing the depth of our work and the promising data we've generated with potential partners and investors."
Cautionary Note Regarding Forward-Looking StatementsThis press release and the statements of MIRA's management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA's potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and other SEC filings, which are on file with the SEC at www.sec.gov and MIRA's website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact InformationHelga Moyainfo@mirapharma.com(786) 432-9792
SOURCE: MIRA Pharmaceuticals
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Coinbase CEO Warns Bitcoin Will 'Take Over As Reserve Currency' If US Fails To Get Debt Under Control
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Does Bitcoin have the potential to become the reserve currency of the world? This is an idea that core believers in the asset have toyed with for years. The reasoning is that disillusionment with the debt-driven fiat system will lead to a mass exodus to Bitcoin due to its scarcity, neutrality and global accessibility. Amid growing U.S. debt concerns, the chorus that the age of Bitcoin is near is growing louder. 'If the electorate doesn't hold congress accountable to reducing the deficit, and start paying down the debt, Bitcoin is going to take over as reserve currency,' Coinbase (NASDAQ:COIN) CEO Brian Armstrong said Wednesday on X in response to data showing that U.S. debt was a hair's breadth away from $37 trillion. Don't Miss: — no wallets, just price speculation and free paper trading to practice different strategies. Grow your IRA or 401(k) with Crypto – . 'I love Bitcoin, but a strong America is also super important for the world,' Armstrong said. 'We need to get our finances under control.' Just the day before, Gemini CEO Tyler Winklevoss posted 'Buy bitcoin' in response to a similar chart. These sentiments come as the rising U.S. debt is likely to negatively impact investor confidence in the country, which could reflect on the dollar. And many believe that the cracks have begun to show as, amid uncertainty, investors have not flocked to the dollar and U.S. Treasury bonds as usual. Economists Charles Collyns and Michael Klein recently warned that if this pattern continues, it could pave the way for multiple reserve currencies to emerge alongside the dollar. Whether Bitcoin will emerge as one of the alternatives remains to be seen. Concerns over the ballooning U.S. debt have grown in recent weeks amid debates over the President Donald Trump's 'big beautiful bill,' which recently passed the House. Trending: New to crypto? on Coinbase. The bill aims to extend and introduce tax cuts, allocate billions to enhance border security, increase the debt ceiling and implement cuts to spending on social programs such as Medicaid and food assistance. In Trump's telling, this bill will put significantly more money in the pockets of Americans and boost defense. However, the Congressional Budget Office said the bill could add at least $3.3 trillion to the U.S. deficit over the next decade, exacerbating concerns about the debt. The bill has drawn flak from even some of Trump's supporters, including Tesla (NASDAQ:TSLA) CEO Elon Musk. 'This massive, outrageous, pork-filled Congressional spending bill is a disgusting abomination,' Musk said on Tuesday. 'Shame on those who voted for it: you know you did wrong. You know it.' But the Trump administration continues to downplay these concerns. Treasury Secretary Scott Bessent told CBS earlier this week that calculations of the impact of the big beautiful bill on the U.S. deficit did not account for anticipated revenue from Trump's controversial tariffs and other initiatives. 'So the deficit this year is going to be lower than the deficit last year, and in two years it will be lower again,' Bessent said. 'The goal is to bring it down over the next four years, leave the country in great shape in 2028.' Read Next: A must-have for all crypto enthusiasts: . Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Image: Shutterstock This article Coinbase CEO Warns Bitcoin Will 'Take Over As Reserve Currency' If US Fails To Get Debt Under Control originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Zeo Energy Corp. Receives Nasdaq Notice on Late Filing of its Form 10-Q
NEW PORT RICHEY, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Zeo Energy Corp. (Nasdaq: ZEO) 'Zeo Energy' or the 'Company'), announced today that, as expected, it received a notice (the 'Notice') from Nasdaq on May 22, 2025, notifying the Company that it is not in compliance with the periodic filing requirements for continued listing set forth in Nasdaq Listing Rule 5250(c)(1) because the Company's Quarterly Report on Form 10-Q for the for the three months ended March 31, 2025 (the '10-Q') was not filed with the Securities and Exchange Commission (the 'SEC') by the required due date of May 15, 2025. As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission (the 'Commission') on April 18, 2025, the Company received a deficiency notice from Nasdaq that the Company was not in compliance with Nasdaq's Listing Rules as set forth in Listing Rule 5250(c)(1) given the Company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the '10-K'). The Company subsequently filed the 10-K on May 28, 2025. This Notice received from Nasdaq has no immediate effect on the listing or trading of the Company's shares. Nasdaq has provided the Company until Monday, June 16, 2025, to submit a plan to regain compliance. If Nasdaq accepts the Company's plan, then Nasdaq may grant the Company an exception until October 13, 2025 to regain compliance with the Nasdaq Listing Rules. The Company continues to work diligently to complete the 10-Q, after which the Company anticipates maintaining compliance with its SEC reporting obligations. This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. About Zeo Energy Corp. Zeo Energy Corp. is a Florida-based regional provider of residential solar, distributed energy, and energy efficiency solutions. Zeo Energy focuses on high-growth markets with limited competitive saturation. With its differentiated sales approach and vertically integrated offerings, Zeo Energy, through its Sunergy business, serves customers who desire to reduce high energy bills and contribute to a more sustainable future. For more information on Zeo Energy Corp., please visit Cautionary Note Regarding Forward-Looking Statements This news release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Exchange Act of 1934, as amended, that are based on beliefs and assumptions and on information currently available to the Company. Such statements may include, but are not limited to, statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions. The words 'anticipate,' 'intend,' 'plan,' 'goal,' 'seek,' 'believe,' 'project,' 'estimate,' 'expect,' 'strategy,' 'future,' 'likely,' 'may,' 'should,' 'will,' and similar references to future periods may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements may include, for example, statements about the filing of the 10-Q, maintaining compliance with SEC reporting obligations and regaining compliance with Nasdaq listing rules. These forward-looking statements are based on information available as of the date of this news release, and current expectations, forecasts, and assumptions, and involve a number of judgments, risks, and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing the Company's views as of any subsequent date, and the Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws. You should not place undue reliance on these forward-looking statements. As a result of a number of known and unknown risks and uncertainties, the Company's actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: (i) the outcome of any legal proceedings that may be instituted against the Company or others; (ii) the Company's success in retaining or recruiting, or changes required in, its officers, key employees, or directors; (iii) the Company's ability to maintain the listing of its common stock and warrants on Nasdaq; (iv) limited liquidity and trading of the Company's securities; (v) geopolitical risk and changes in applicable laws or regulations; (vi) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (vii) operational risk; (viii) litigation and regulatory enforcement risks, including the diversion of management time and attention and the additional costs and demands on the Company's resources; and (ix) other risks and uncertainties, including those included under the heading 'Risk Factors' in the Company's Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2024 and in its subsequent periodic reports and other filings with the SEC. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company, its respective directors, officers or employees or any other person that the Company will achieve its objectives and plans in any specified time frame, or at all. The forward-looking statements in this news release represent the views of the Company as of the date of this news release. Subsequent events and developments may cause that view to change. However, while the Company may elect to update these forward-looking statements at some point in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of the Company as of any date subsequent to the date of this news release. Zeo Energy Corp. Contacts For Investors:Tom Colton and Greg BradburyGateway GroupZEO@ For Media:Zach KadletzGateway GroupZEO@
Yahoo
2 hours ago
- Yahoo
47.7% of Warren Buffett's $282 Billion Portfolio Is Invested in 3 Stocks That Could Net Berkshire Hathaway $1.6 Billion in Dividends This Year
Warren Buffett's simple investing strategy propeled Berkshire Hathaway to market-beating returns since 1965. Buffett likes investing in companies that return money to shareholders through dividends, because they compound his returns more quickly. Three of Berkshire's holdings, which represent almost half of the value of its portfolio, could deliver $1.6 billion in dividend payments this year. 10 stocks we like better than Apple › Warren Buffett has been the CEO of the Berkshire Hathaway holding company since 1965. He plans to step down at the end of this year, but he will continue serving as chairman of the board. Even without the Oracle of Omaha at the helm, Buffett's successful brand of long-term investing is expected to continue. Buffett typically invests in growing companies with reliable profits and strong management teams. He especially likes companies with shareholder-friendly initiatives like dividend schemes and stock buyback programs, because they compound his returns much faster. Buffett's strategy has been so successful that a $1,000 investment in Berkshire stock in 1965 would have been worth a staggering $44.7 million at the end of 2024. The same investment in the S&P 500 would have grown to just $342,906. Berkshire holds a number of dividend-paying stocks, but three of them represent 47.7% of the total value of its $282 billion portfolio of publicly traded securities. Assuming Buffett and his team don't sell a single share in those companies, they could net the conglomerate a whopping $1.6 billion in dividends this year alone. Apple (NASDAQ: AAPL) is the $3 trillion juggernaut responsible for some of the world's most popular consumer devices including the iPhone, iPad, and Mac line of computers. Buffett and his team spent around $38 billion buying Apple shares between 2016 and 2023, and the value of that position grew to an eye-popping $170 billion heading into 2024. It accounted for more than half of the value of Berkshire's entire portfolio at that point, so Buffett and his team sold half the position last year to reduce some of the concentration risk. Apple is still Berkshire's largest holding with a 21.7% weighting in its portfolio, but the conglomerate's performance is now less susceptible to the fate of one single stock. So far this year, Berkshire earned a quarterly dividend payment of $0.25 per share from Apple on Feb. 13, and a second payment of $0.26 per share on May 15. It's likely to receive two more payments of $0.26 per share this year, bringing its total per-share payments to $1.03 in 2025. The conglomerate currently holds 300 million Apple shares, so that would translate to $309 million in dividends this calendar year. But the value of Berkshire's Apple position is currently $61 billion, so its dividend yield is just 0.5%. Cash in the bank pays a better return than that right now, but it's still a nice bonus on top of the incredible capital growth Berkshire earned in its time as an Apple shareholder. American Express (NYSE: AXP) is a global payments giant with a presence in over 200 countries. Unlike its competitors, the company operates a closed-loop ecosystem, which means it runs its own payments network, issues its own cards to consumers and businesses, and also funds the underlying lines of credit. The result is multiple revenue streams and significantly more control over its operating performance. Berkshire spent around $1.3 billion accumulating a stake in American Express during the 1990s, and it has been a cornerstone of the conglomerate's portfolio ever since. Berkshire currently owns one-fifth of the entire company, and its 151.6 million shares are currently worth $44.9 billion, which accounts for 15.9% of the value of its portfolio. So far in 2025, Berkshire has earned two quarterly dividend payments from American Express. The first was for $0.70 per share on Feb. 10, and the second was for $0.82 per share on May 9. There will likely be two more quarterly payments of $0.82 per share this year, translating to total per-share payments of $3.16 in 2025. Assuming Berkshire doesn't sell any of its 151.6 million shares, it stands to earn $479 million in dividends this year alone. That equals a yield of around 1.1%. Coca-Cola (NYSE: KO) is the world's largest beverage company. It's home to over 200 individual brands including its namesake, Schweppes, Powerade, Vitamin Water, Sprite, and Fanta, which it sells in more than 200 countries. Coca-Cola has built an incredible distribution network, which includes popular fast-food chains like McDonald's, to ensure its products are constantly in front of consumers. Buffett accumulated 400 million shares in Coca-Cola on Berkshire's behalf between 1988 and 1994, spending around $1.3 billion in total. He has never sold a share, and the position is now worth a whopping $28.5 billion, which accounts for 10.1% of the conglomerate's portfolio. Coca-Cola also paid Berkshire $776 million in dividends last year, so the investing powerhouse basically recoups its initial $1.3 billion outlay every two years on top of the incredible capital growth. Coca-Cola increased its dividend at the start of 2025, paying $0.51 per share during the first quarter. It's likely to remain at that level for the rest of the year if history is any guide, placing Berkshire on track to earn $2.04 in dividends per share in 2025. Assuming it doesn't sell any of its 400 million shares, that means the conglomerate stands to earn $816 million in payments (a yield of 2.8%). Berkshire's Coca-Cola position is one of the best examples of Buffett's investing strategy in action, as he relies on time and the magic of compounding to do the heavy lifting for him. Before you buy stock in Apple, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Apple wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,395!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $858,011!* Now, it's worth noting Stock Advisor's total average return is 997% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 American Express is an advertising partner of Motley Fool Money. Anthony Di Pizio has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Apple and Berkshire Hathaway. The Motley Fool has a disclosure policy. 47.7% of Warren Buffett's $282 Billion Portfolio Is Invested in 3 Stocks That Could Net Berkshire Hathaway $1.6 Billion in Dividends This Year was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
